
Assembly Biosciences (ASMB) Stock Forecast & Price Target
Assembly Biosciences (ASMB) Analyst Ratings
Bulls say
Assembly Biosciences is showing strong potential for growth and success, driven by their progress in clinical trials and potential partnerships with major pharmaceutical companies like Gilead. With multiple exciting drug candidates in the pipeline and sufficient funding for the next decade, the company is well-positioned for long-term success. However, risks related to clinical development and potential delays should also be considered when evaluating their future prospects and stock valuation.
Bears say
Assembly Biosciences is facing challenges in its pipeline with its investigational therapies likely facing strong competition and a low PoS (probability of success). Additionally, one of its key candidates, ABI-4334, has been deprioritized and the company is now seeking a partner. While potential success in cholestatic liver diseases could bring in significant revenue, the lack of progress in other areas and the need for potential partnerships may weigh on the company's financials and stock performance.
This aggregate rating is based on analysts' research of Assembly Biosciences and is not a guaranteed prediction by Public.com or investment advice.
Assembly Biosciences (ASMB) Analyst Forecast & Price Prediction
Start investing in Assembly Biosciences (ASMB)
Order type
Buy in
Order amount
Est. shares
0 shares